促红细胞生成素介导体细胞因子 17F 减轻脓毒症引起的肠道微生物群失调和屏障功能障碍。

Erythropoietin-mediated IL-17 F attenuates sepsis-induced gut microbiota dysbiosis and barrier dysfunction.

机构信息

Department of Anesthesia and Critical Care, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Department of Biochemistry, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.

The First Affiliated Hospital of Wenzhou Medical University, The First Clinical College of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.

出版信息

Biomed Pharmacother. 2023 Sep;165:115072. doi: 10.1016/j.biopha.2023.115072. Epub 2023 Jun 28.

Abstract

Septic gut damage is critical in the progression of sepsis and multiple organ failure, characterized by gut microbiota dysbiosis and epithelium deficiency in the gut barrier. Recent studies highlight the protective effects of Erythropoietin (EPO) on multiple organs. The present study found that EPO treatment significantly alleviated the survival rate, suppressed inflammatory responses, and ameliorated intestine damage in mice with sepsis. EPO treatment also reversed sepsis-induced gut microbiota dysbiosis. The protective role of EPO in the gut barrier and microbiota was impaired after EPOR knockout. Notably, we innovatively demonstrated that IL-17 F screened by transcriptome sequencing could ameliorate sepsis and septic gut damage including gut microbiota dysbiosis and barrier dysfunction, which was verified by IL-17 F-treated fecal microbiota transplantation (FMT) as well. Our findings highlight the protection effects of EPO-mediated IL-17 F in sepsis-induced gut damage by alleviating gut barrier dysfunction and restoring gut microbiota dysbiosis. EPO and IL-17 F may be potential therapeutic targets in septic patients.

摘要

脓毒症相关的肠道损伤是脓毒症和多器官功能衰竭进展的关键,其特征是肠道微生物失调和肠道屏障的上皮细胞缺失。最近的研究强调了促红细胞生成素 (EPO) 对多个器官的保护作用。本研究发现,EPO 治疗可显著提高脓毒症小鼠的生存率,抑制炎症反应,改善肠道损伤。EPO 治疗还可逆转脓毒症引起的肠道微生物失调。在 EPOR 敲除后,EPO 在肠道屏障和微生物群中的保护作用受损。值得注意的是,我们创新性地证明,通过转录组测序筛选出的白细胞介素 17F(IL-17F)可以改善脓毒症和脓毒症相关的肠道损伤,包括肠道微生物失调和屏障功能障碍,这一点通过白细胞介素 17F 处理的粪便微生物群移植(FMT)也得到了验证。我们的研究结果强调了 EPO 介导的白细胞介素 17F 在脓毒症相关肠道损伤中的保护作用,通过缓解肠道屏障功能障碍和恢复肠道微生物失调来发挥作用。EPO 和白细胞介素 17F 可能是脓毒症患者的潜在治疗靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索